SOBI:OMXSTOSwedish Orphan Biovitrum AB Analysis

Swedish Orphan Biovitrum trades at SEK 439.2, just below its 20‑day SMA of 439.3 but comfortably above the 50‑day (SEK 425.9) and 200‑day (SEK 357.9) averages, indicating a short‑term bullish bias. The RSI sits at 53.9, suggesting neutral momentum, while the MACD histogram is negative and the signal line is labeled bearish, warning of potential near‑term downside pressure. Support is anchored at SEK 428.8 and resistance at SEK 451.8, a range that recent price action respects. Volatility over the past 30 days is elevated at 19.4% but beta is low at 0.38, implying the stock moves less than the broader market. Valuation metrics are stretched: a trailing P/E of 166× dwarfs the industry average of 24×, while the DCF fair value of SEK 198.9 suggests the market is pricing in a premium of roughly 120%. Despite this, forward earnings estimates imply a forward P/E of 28× and analysts project a modest upside of 7%, reflecting confidence in the pipeline and recent 24% revenue growth YoY. Recent Q1 FY2026 results highlighted a jump in adjusted EBITDA margin to 38% and strong commercial execution across hemophilia and immunology products. The company also announced encouraging Phase 3 data for its Tryngolza (olezarsen) program, reinforcing long‑term growth potential. With no dividend and a high payout‑ratio of zero, cash generation remains critical, and the balance sheet shows substantial debt (SEK 19.1 bn) relative to equity. Overall, the stock sits at the intersection of strong fundamentals and a markedly overvalued price, creating a nuanced investment picture.